Nomeri 3 (2025): May-Iyun
88-94
2025-06-28
Ochiq kirish

PLEVRAL EFFUZIYA BILAN ASORATLANGAN SHIFOXONADAN TASHQARI PNEVMONIYA BILAN YOTQIZILGAN BOLALARNI BOSHQARISH VA DAVOLASH NATIJALARI

Aminova Nigina Aminovna
DOI: https://doi.org/10.56121/2181-3612-2025-3-88-94

Qabul qilingan: 2025-06-03 20:09:27

Nashr etilgan: 2025-06-28

PDF (ruscha)
Crossmark Crossmark

Annotatsiya

Ushbu tadqiqotning maqsadi plevra effyuziyasi bilan asoratlangan shifoxonadan tashqari  pnevmoniya bilan kasallangan bolalarni kasalxonaga yotqizish holatlarini tekshirish. Tadqiqotga 2022-yil 1-fevraldan 2025-yil 25-fevralgacha viloyat bolalar ko`p tarmoqli tibbiyot markazining pulmonologiya va jarrohlik bo‘limlariga pnevoniya bo‘yicha har qanday chiqarish kodi bilan yotqizilgan, ultratovush tekshiruvi natijalariga ko‘ra effuziya/empiema qayd etilgan 18 yoshgacha bo‘lgan, jiddiy qo‘shimcha kasalliklari bo‘lmagan bolalar ishtirok etdi. O'rganish davrida 87 nafar jiddiy komorbidsiyasiz bolalar tasdiqlangan ShTP bo`yicha kasalxonaga yotqizilgan. Kasalxonada yotishning o'rtacha davomiyligi 9 kun (1-Q3 6-11 kun), 27 (31%) reanimatsiya va intensiv terapiya bo`limiga yotqizilgan. Ko'pchilik (61,70%)  drenaj qo`yish muolajasi o`tqizildi. Kasalxonada qolish muddati efüzyon miqdori bilan bog'liq emas, balki drenaj vaqti bilan bog'liq ekanligi qayd etildi (drenajda kuniga 0,60 kun ko'proq qolish, 95% CI 0,19-1,0 kun). Mikrobiologik diagnostika qon baktereologik tekshiruviga (9, 10%) qaraganda plevra suyuqligining PSR tahlili (43/59, 73%) bilan tez-tez amalga oshirildi; Asosiy etiologik patogenlar S. pneumoniae (33,38%), S. pyogenes (14,87%) va S. aureus (7,8%) edi. Tor spektrli antibiotik (masalan, amoksitsillin) bilan oqizish murakkab plevral efüzyon bilan patogen aniqlanganda, etiologik agent aniqlanmagan holatga qaraganda sezilarli darajada tez-tez uchraydi (68% ga nisbatan 24%, p <0,001). Shunday qilib, ShTP bilan kasallangan bolalar odatda uzoq vaqt davomida kasalxonaga yotqizilgan. Jarrohlik drenajlash kasalxonada o`tqazilgan o`rin-kunni qisqarishi bilan bog'liq edi. Plevral suyuqlik tekshiruvi ko'pincha mikrobiologik tashxisni osonlashtirdi, bu o'z-o'zidan antibiotik terapiyasi  bilan bog'liq edi.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Kaiser SV, Rodean J, Coon ER, Mahant S, Gill PJ, Leyenaar JK. Common diagnoses and costs in pediatric hospitalization in the US.JAMA Pediatr2021

  2. Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER randomized clinical trial. JAMA Pediatr. 2021;175:475–82.

  3. Bielicki JA, Stohr W, Barratt S, et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial. JAMA. 2021;326:1713–24.

  4. Williams DJ, Creech CB, Walter EB et al. Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: The SCOUT-CAP randomized clinical trial.JAMA Pediatr2022

  5. Langley JM, Kellner JD, Solomon N, et al. Empyema associated with community-acquired pneumonia: a pediatric investigator’s collaborative network on infections in Canada (PICNIC) study. BMC Infect Dis. 2008;8:129.

  6. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis.2010;201:32–41.

  7. Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis. 2010;50:805–13.

  8. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125:26–33.

  9. Strachan RE, Snelling TL, Jaffe A. Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine. Bull World Health Organ. 2013;91:167–73.

  10. Ampofo K, Herbener A, Blaschke AJ, et al. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J. 2010;29:905–9.

  11. Saxena S, Atchison C, Cecil E, Sharland M, Koshy E, Bottle A. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England. J Infect. 2015;71:428–36.

  12. Olarte L, Barson WJ, Barson RM, et al. Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2017;64:1699–704.

  13. Liese JG, Schoen C, van der Linden M, et al. Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010–2017: a nationwide surveillance study. Clin Microbiol Infect. 2019;25:857–64.

  14. Pernica JM, Moldovan I, Chan F, Slinger R. Real-time polymerase chain reaction for microbiological diagnosis of parapneumonic effusions in canadian children.Can J Infect Dis Med Microbiol. 2014;25:151–4.

  15. Megged O. Characteristics of streptococcus pyogenes versus Streptocoсcus pneumoniae pleural empyema and pneumonia with pleural effusion in children. Pediatr Infect Dis J. 2020;39:799–802.

  16. Rix-Trott K, Byrnes CA, Gilchrist CA, et al. Surveillance of pediatric parapneumonic effusion/empyema in New Zealand. Pediatr Pulmonol.2021;56:2949–57.

  17. Bradley JS, Byington CL, Shah SS, et al. The management of community acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the PIDS and IDSA. Clin Infect Dis. 2011;53:e25–76

  18. “Paediatric complicated pneumonia. : Diagnosis and management of empyema” https://cps.ca/en/documents/position/complicated-pneumoniaempyema. Last Accessed 2022 July 17

  19. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30:289–94.

  20. de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ. Bush A. Complicated pneumonia in children. Lancet. 2020;396:786–98.

  21. Islam S, Calkins CM, Goldin AB, et al. The diagnosis and management of empyema in children: a comprehensive review from the APSA outcomes and clinical trials committee. J Pediatr Surg. 2012;47:2101–10.

  22. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Immunization coverage report for school pupils in Ontario: 2018-19 school year. Toronto: Queen’s Printer for Ontario; 2020.

  23. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835–45.

  24. Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory Syncytial Virus in children younger than 5 years in England during the covid-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis. 2023;23:56–66.

  25. Groves HE, Piche-Renaud PP, Peci A, et al. The impact of the covid-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: a population-based study. Lancet Reg Health Am. 2021;1:100015.

  26. Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between Respiratory Syncytial Virus activity and pneumococcal disease in infants: a time series analysis of us hospitalization data. PLoS Med. 2015;12:e1001776.

  27. Shrestha S, Foxman B, Weinberger DM, Steiner C, Viboud C. Rohani P. identifying the interaction between influenza and pneumococcal pneumonia using incidence data. Sci Transl Med. 2013;5:191ra184.

  28. Rybak A, Levy C, Angoulvant F, et al. Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France. JAMA Netw Open. 2022;5:e2218959.

  29. Danino D, Ben-Shimol S, Van Der Beek BA et al. Decline in pneumococcaldisease in young children during the COVID-19 pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneucoccal carriage: A prospective cohort study.Clin Infect Dis2021

  30. Chan KF, Ma TF, Sridhar S, Lam DC, Ip MS, Ho PL. Changes in etiology and clinical outcomes of pleural empyema during the COVID-19 pandemic.Microorganisms2023;11

  31. Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US. JAMA Netw Open. 2021;4:e2141779.

  32. Sadani S, Das M. Assessment of bacteriological profile and outcome of empyema thoracis of hospitalized children: a single center experience. Pediatr Respirol Crit Care Med. 2022;6:47–53.

Mualliflar haqida

Aminova Nigina Aminovna
niginaaminzoda9@gmail.com
Samarqand davlat tibbiyot universiteti
https://orcid.org/0009-0003-5426-8600 (avtorizatsiyalanmagan)

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Qanday iqtibos keltirish kerak

1.
PLEVRAL EFFUZIYA BILAN ASORATLANGAN SHIFOXONADAN TASHQARI PNEVMONIYA BILAN YOTQIZILGAN BOLALARNI BOSHQARISH VA DAVOLASH NATIJALARI. MSU [Internet]. 2025 Jun. 28 [cited 2026 Mar. 2];(3):88-94. Available from: https://fdoctors.uz/index.php/journal/article/view/167
Crossref
Scopus
Google Scholar
Europe PMC

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.


ISSN 2181-3612 (Online)